{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:15:13Z","timestamp":1793643313538,"version":"4.5.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/qco.0b013e328359a56e","type":"journal-article","created":{"date-parts":[[2012,10,18]],"date-time":"2012-10-18T19:11:06Z","timestamp":1350587466000},"page":"605-611","source":"Crossref","is-referenced-by-count":30,"title":["Making sense of posaconazole therapeutic drug monitoring"],"prefix":"10.1097","volume":"25","author":[{"given":"Michelle R.","family":"Ananda-Rajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210205","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"R2-2-20210205","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-2-20210205","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R4-2-20210205","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R5-2-20210205","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 Registry Study.","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"R6-2-20210205","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1128\/AAC.01423-10","article-title":"Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach.","volume":"55","author":"Ananda-Rajah","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-2-20210205","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R8-2-20210205","first-page":"1068","article-title":"The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.","volume":"91","author":"Pagano","year":"2006","journal-title":"Haematologica"},{"key":"R9-2-20210205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2011.051995","article-title":"Comparative clinical effectiveness of prophylactic voriconazoleposaconazole to fluconazoleitraconazole in patients with acute myeloid leukemiamyelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.","volume":"97","author":"Ananda-Rajah","year":"2012","journal-title":"Haematologica"},{"key":"R10-2-20210205","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.bbmt.2010.04.017","article-title":"Efficacy, safety and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem-cell transplant recipients.","volume":"17","author":"Winston","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-2-20210205","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/jac\/dkq121","article-title":"Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.","volume":"65","author":"Vehreschild","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R12-2-20210205","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3324\/haematol.2011.044636","article-title":"Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009.","volume":"96","author":"Nicolle","year":"2011","journal-title":"Haematologica"},{"key":"R13-2-20210205","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.2011.053058","article-title":"Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.","volume":"97","author":"Girmenia","year":"2012","journal-title":"Haematologica"},{"key":"R14-2-20210205","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1093\/jac\/dks189","article-title":"Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.","volume":"67","author":"Auberger","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R15-2-20210205","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1128\/AAC.00157-06","article-title":"Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.","volume":"50","author":"Gubbins","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-2-20210205","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R17-2-20210205","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"R18-2-20210205","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokineticpharmacodynamic profile of posaconazole.","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R20-2-20210205","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.05900-11","article-title":"Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring.","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R21-2-20210205","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R22-2-20210205","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma.","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R23-2-20210205","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications.","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R24-2-20210205","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","article-title":"Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-2-20210205","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1128\/AAC.00163-06","article-title":"In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.","volume":"50","author":"Sabatelli","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-2-20210205","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/clpt.2010.261","article-title":"Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections.","volume":"89","author":"Cornely","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R27-2-20210205","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1128\/AAC.00240-09","article-title":"3rd, Rinaldi MG, Pennick G, et al. Posaconazole therapeutic drug monitoring: a reference laboratory experience.","volume":"53","author":"Thompson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-2-20210205","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults.","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R29-2-20210205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2010.11.021","article-title":"A postmarketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.","volume":"37","author":"Bryant","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"R30-2-20210205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10096-011-1288-9","article-title":"Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.","volume":"31","author":"Eiden","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R31-2-20210205","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijantimicag.2012.02.002","article-title":"Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.","volume":"39","author":"Hoenigl","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"R32-2-20210205","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1128\/AAC.00150-10","article-title":"Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method.","volume":"54","author":"Neubauer","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R33-2-20210205","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"key":"R34-2-20210205","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1128\/AAC.01671-10","article-title":"Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the nonprotein-bound serum concentration.","volume":"55","author":"Lignell","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R35-2-20210205","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.00663-08","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects.","volume":"53","author":"Conte","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-2-20210205","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01407-09","article-title":"Intracellular concentrations of posaconazole in different compartments of peripheral blood.","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R37-2-20210205","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1128\/AAC.01396-09","article-title":"Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients.","volume":"54","author":"Conte","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R38-2-20210205","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.1128\/AAC.00637-11","article-title":"Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis.","volume":"55","author":"Campoli","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-2-20210205","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.05937-11","article-title":"Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.","volume":"56","author":"Cornely","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R40-2-20210205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FTD.0b013e31823cef77","article-title":"Posaconazole serum level on day 2 predicts steady state posaconazole serum level.","volume":"34","author":"Green","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R42-2-20210205","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1111\/j.1439-0507.2011.02020.x","article-title":"Optimising absorption of posaconazole.","volume":"54","author":"Green","year":"2011","journal-title":"Mycoses"},{"key":"R43-2-20210205","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1128\/AAC.00062-11","article-title":"Relevance of timing for the determination of posaconazole plasma concentrations.","volume":"55","author":"Heinz","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R44-2-20210205","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R45-2-20210205","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1128\/AAC.50.5.1881-1883.2006","article-title":"Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.","volume":"50","author":"Sansone-Parsons","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R46-2-20210205","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-2-20210205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R49-2-20210205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1086\/597110","article-title":"Omeprazole significantly reduces posaconazole serum trough level.","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R50-2-20210205","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults.","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"R51-2-20210205","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R52-2-20210205","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1128\/AAC.01325-10","article-title":"Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy.","volume":"55","author":"Shields","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-2-20210205","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1128\/AAC.00222-12","article-title":"A single dose phase I study to evaluate the pharmacokinetics of posaconazole new tablet and capsule formulations relative to oral suspension.","volume":"56","author":"Krishna","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Opinion in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QCO.0b013e328359a56e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:19:51Z","timestamp":1620973191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001432-201212000-00002"}},"subtitle":["a practical approach"],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qco.0b013e328359a56e","relation":{},"ISSN":["0951-7375"],"issn-type":[{"value":"0951-7375","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}